Valuation: China Isotope & Radiation Corporation

Market Cap 473.92Cr 548.59Cr 70Cr 62Cr 57Cr 53Cr 99Cr 6.78TCr 100.36Cr 683.58Cr 266.63Cr 3.3TCr 262.66Cr 256.98Cr 11TCr P/E 2024
8.03x
P/E 2025 17.7x
Enterprise Value 485.81Cr 562.34Cr 72Cr 63Cr 59Cr 54Cr 101.07Cr 6.95TCr 102.88Cr 700.72Cr 273.32Cr 3.39TCr 269.25Cr 263.43Cr 12TCr EV / Sales 2024
0.42x
EV / Sales 2025 0.82x
Free-Float
91.21%
Yield 2024
3.74%
Yield 2025 1.69%
06/07 China Isotope to Form JV With Associate MT
03/07 China Isotope & Radiation Corporation and CNNC Yuanke Enter into Shareholders? Agreement to Establish Joint Venture Company CNNC Fuyuan CI
18/06 China Isotope & Radiation Corporation Approves Final Dividend for the Year Ended 31 December 2025, Payable on Before 17 August 2026 CI
18/06 China Isotope & Radiation Corporation Appoints Zhang Guoliang as A Member of Legal Affairs Committee of the Board and A Member of Science and Technology Innovation Committee of the Board CI
27/05 China Isotope Proposes Auditor Change MT
26/05 China Isotope & Radiation Corporation Announces Ma Xiaoyu Resignation of Ma Xiaoyu as an Executive Director Member of the Legal Affairs Committee Science and Technology Innovation Committee, Effective May 26, 2026 CI
27/03 China Isotope & Radiation final cash dividend of RMB0.2264 per share RE
27/03 China Isotope & Radiation Corporation Proposes Final Dividend for the Year Ended December 31, 2025, Payable Before 17 August 2026 CI
27/03 China Isotope & Radiation Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
19/03 China Isotope & Radiation to buy 51% stake in Hunan Huifeng Engineering Detection RE
14/03 China Isotope & Radiation Corporation, Zhonghe Headway and the People?s Government of Maoming Municipality Enter Strategic Cooperation Agreement CI
13/03 China Isotope & Radiation says co and Zhonghe Headway enter strategic cooperation agreement with Maoming municipality RE
02/03 China Isotope & Radiation's Unit Gets China Nod for Market Launch of Breath Analyzer MT
1 day+1.72%
1 week-2.50%
Current month-2.00%
1 month-4.67%
3 months-8.09%
6 months-22.40%
Current year-15.10%
1 week 16.86
Extreme 16.86
17.77
1 month 16.5
Extreme 16.5
18.7
Current year 16.5
Extreme 16.5
24.28
1 year 15.2
Extreme 15.2
25
3 years 9.03
Extreme 9.03
25
5 years 9.03
Extreme 9.03
29.95
10 years 9.03
Extreme 9.03
35.4
Manager TitleAgeSince
Chief Executive Officer 55 02/08/2024
Corporate Secretary - 30/08/2024
Corporate Secretary - 30/08/2024
Director TitleAgeSince
Director/Board Member 64 30/06/2023
Director/Board Member 46 25/02/2021
Director/Board Member 57 22/02/2017
Change 5-day change 1-year change 3-year change Capi.($)
+1.72%-2.50%+7.19%+27.23% 69Cr
-0.36%-3.10%+230.47%+298.83% 2TCr
-1.22%-5.09%-43.44%-27.84% 940.32Cr
-0.84%-1.31%+41.50%+18.49% 681.07Cr
+2.15%+8.05%+252.86%-19.85% 597.33Cr
-1.59%+5.91%-12.16%-23.02% 561.92Cr
-10.00%+2.06%+88.80%+110.73% 505.63Cr
+1.76%-5.04%-47.89% - 434.76Cr
0.00%-4.24%-26.67%-28.44% 405.28Cr
-1.68%-2.81%-16.61%-39.76% 276.18Cr
Average -1.01%-1.82%+47.40%+35.15% 647.02Cr
Weighted average by Cap. -1.03%-2.24%+92.96%+98.47%

Financials

2024 2025
Net sales 757.48Cr 876.81Cr 111.83Cr 98Cr 91Cr 84Cr 157.59Cr 11TCr 160.41Cr 1.09TCr 426.16Cr 5.28TCr 419.82Cr 410.74Cr 18TCr 718.77Cr 832Cr 106.11Cr 93Cr 87Cr 80Cr 149.54Cr 10TCr 152.22Cr 1.04TCr 404.38Cr 5.01TCr 398.36Cr 389.75Cr 17TCr
Net income 41Cr 47Cr 6Cr 5.28Cr 4.9Cr 4.51Cr 8.46Cr 581.37Cr 8.61Cr 59Cr 23Cr 283.57Cr 23Cr 22Cr 983.78Cr 33Cr 38Cr 4.83Cr 4.25Cr 3.95Cr 3.63Cr 6.81Cr 468.11Cr 6.93Cr 47Cr 18Cr 228.32Cr 18Cr 18Cr 792.12Cr
Net Debt -11Cr -13Cr -1.61Cr -1.41Cr -1.31Cr -1.21Cr -2.27Cr -155.74Cr -2.31Cr -16Cr -6.13Cr -76Cr -6.04Cr -5.91Cr -263.53Cr 12Cr 14Cr 1.75Cr 1.54Cr 1.43Cr 1.32Cr 2.47Cr 169.9Cr 2.52Cr 17Cr 6.69Cr 83Cr 6.59Cr 6.44Cr 287.5Cr
Logo China Isotope & Radiation Corporation
China Isotope & Radiation Corp is a China-based company mainly engaged in the research, development, manufacturing and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products. The Company operates five business segments. Pharmaceuticals segment is engaged in providing imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test (UBT) kits and analyzers and in vitro diagnostic reagents and kits. Radioactive Source Products segment is engaged in providing various medical and industrial radioactive sources products as well as provision of related technical services. Irradiation segment is engaged in providing sterilization services. Radiation Therapy Equipment and Related Services segment is engaged in manufacturing Radiation therapy equipment. Other Businesses segment is engaged in providing trade services in relation to imported radioactive source, medical nuclides, imported radiopharmaceuticals, and other products.
Employees
3,578
Date Price Change Volume
23/26/23 HK$17.15 +1.72% 33,800
22/26/22 HK$16.86 -1.00% 83,600
21/26/21 HK$17.03 +0.18% 54,000
20/26/20 HK$17.00 +1.19% 36,400
17/26/17 HK$16.80 -4.49% 2,94,400

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1763 Stock